Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Freedom Finance and Binance Join Forces in Digital Assets 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance 
Warner Bros. Discovery Weighs Renewed Sale Talks With Paramount Skydance Amid Netflix Deal Review 
CAMBRIDGE, Mass., April 26, 2018 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, May 3, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the first quarter of 2018.
To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 6079429. A live webcast of the presentation will be available on the Investors & Media section of the Editas website.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts
Media:
Cristi Barnett
(617) 401-0113
[email protected]
Investors:
Mark Mullikin
(617) 401-9083
[email protected]
